Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.59 |
| ▸ | NOS1 | P29475 | 4/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29520931 | 1.00 | ROCK2 (0.59) | ROCK2NOS1ROCK1MAPTGAA | |
| Hydrochloric Acid SCHEMBL27782875 | 0.98 | ROCK2 (0.57) | ROCK2NOS1ROCK1MAPTGAA | |
| Fumaric Acid SCHEMBL5990331 | 0.86 | ROCK2 (0.48) | ROCK2NOS1ROCK1MAPTGAA | |
| Fumaric Acid SCHEMBL5990339 | 0.86 | ROCK2 (0.48) | ROCK2NOS1ROCK1MAPTGAA | |
| SCHEMBL27663173 | 0.84 | FGFR1 (0.74) | ROCK2NOS1ROCK1MAPTGAA | |
| SCHEMBL29741144 | 0.83 | FGFR1 (0.72) | NOS1MAPTGAAMETAP2KDM4E | |
| SCHEMBL177086 | 0.83 | FGFR1 (0.72) | NOS1MAPTGAAMETAP2KDM4E | |
| SCHEMBL17291792 | 0.82 | NOS1 (0.82) | ROCK2NOS1ROCK1MAPTGAA | |
| Tert-Butyl Formate SCHEMBL28317369 | 0.81 | ROCK1 (0.44) | ROCK2NOS1ROCK1MAPTGAA | |
| SCHEMBL3540025 | 0.74 | NOS1 (1.00) | ROCK2NOS1ROCK1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954826-A | Compound, preparation method and application thereof, lithium ion battery electrolyte additive and electrolyte | 华鼎国联动力电池有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-105734586-B | A kind of organic-silicon-modified corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2018-04-10 | — | — | CN | claimed |
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | claimed |
| CN-105734586-A | Organosilicon-modified corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| EP-2493302-A1 | HEXAHYDROCYCLOPENTYL[F]INDAZOLE PYRIDYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2011053567-A1 | HEXAHYDROCYCLOPENTYL[F]INDAZOLE PYRIDYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | claimed |
| CN-101528707-A | 2- [ 1-phenyl-5-hydroxy or methoxy-4 alpha-methyl-hexahydrocyclopenta [ f ] indazol-5-yl ] ethylphenyl derivatives useful as glucocorticoid receptor ligands | MERCK & CO INC (US) | 2009-09-09 | — | — | CN | claimed |
| WO-2007071686-A1 | COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, AN OXIDATION BASE AND A PARTICULAR COUPLER | L'ORÉAL (FR) | 2007-06-28 | — | — | WO | claimed |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1428510-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | claimed |
| US-4168953-A | Oxidation hair dyes based upon tetraaminopyrimidine developers and monohydroxyindazole couplers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1979-09-25 | — | — | US | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-4723020-A | Chromogenic amino acid esters and peptide esters | MILES LABORATORIES, INC. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0157360-A2 | Chromogenic esters of amino acids and peptides, processes for their preparation, use of these agents in methods of analysis and agents for detection of esterolytic and/or proteolytic enzymes | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| US-4168953-A | Oxidation hair dyes based upon tetraaminopyrimidine developers and monohydroxyindazole couplers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1979-09-25 | — | — | US | disclosed |
| US-3939084-A | Functional fluid compositions containing substituted pyrimidines | MONSANTO COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | ROCK2 98/4885NOS1 1180/4885ROCK1 39/4885 |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | ROCK2 2/4885NOS1 352/4885ROCK1 1/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885NOS1 1773/4885ROCK1 4/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ROCK2 101/4885NOS1 3240/4885ROCK1 41/4885 |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | KRT18, CDC73, PYCR1 | ROCK2 4817/4885NOS1 2710/4885ROCK1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.